耐药结核病实验室诊断方法的研究进展  

Progress on Laboratory Diagnostic Methods for Drug-resistant Tuberculosis

作　　者：李瑜琴[1] 陈玲[1] 

机构地区：[1]遵义医学院附属医院呼吸二科,贵州省遵义市563000

出　　处：《实用心脑肺血管病杂志》2017年第12期8-11,共4页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：国家自然科学基金资助项目(81360002)

摘　　要：20世纪90年代以来全球结核病疫情开始回升,而结核分枝杆菌耐药是导致结核病发病率升高的重要原因之一,我国是全球30个结核病高负担国家之一。近年来,由于诊断延迟、化疗不当或管理不善等而导致耐药结核病增多,治疗难度增加,常需联合二线抗结核药物,但目前临床上所用二线抗结核药物不仅毒副作用较大、费用较昂贵,且整体控制效果较差。近年来,随着分子生物学技术发展,结核病诊断技术尤其是耐药结核病诊断技术突飞猛进。本文主要综述了耐药结核病实验室诊断方法的研究进展,旨在为耐药结核病的诊治提供参考。Global tuberculosis epidemic situation began to rise due to mycobacterium tuberculosis resistance since the 1990s,China is one of thirty high tuberculosis burden countries in the world. In recent years, drug-resistant tuberculosis significantly increased due to delayed diagnosis, improper chemotherapy, poor management and so on, treatment of drug-resistant tuberculosis is more difficult which need combination of second-line antituberculosis drugs,but now second-line antituberculosis drugs have high risk of toxic and side effects and poor overall control effect, mostly are expensive. As the advances in molecular biology, diagnostic techniques for tuberculosis especially for drug-resistant tuberculosis rapidly advanced. This paper reviewed the progress on laboratory diagnostic methods for drug-resistant tuberculosis,in order to provide a reference for the clinical diagnosis and treatment.

关 键 词：结核 耐药 结核分枝杆菌 诊断 综述 

分 类 号：R52[医药卫生—内科学]